Arend W P, Leung D Y
Department of Medicine, University of Colorado Health Sciences Center, Denver 80262.
Immunol Rev. 1994 Jun;139:71-8. doi: 10.1111/j.1600-065x.1994.tb00857.x.
In summary, IL-1ra is a unique cytokine that binds avidly to cell surface receptors for IL-1 without inducing any detectable intracellular responses. Adherent IgG and LPS induce IL-1ra production in human monocytes through different mechanisms. IL-1ra has been shown to be an effective competitive inhibitor of IL-1 both in vitro and in vivo (Arend 1993). The possibility exists that stimulation or enhancement of endogenous IL-1ra production may be an efficacious therapeutic approach in human diseases where local IL-1 may play an important role in pathophysiology. Our studies have demonstrated that IL-1ra production is induced in human monocytes in vitro by either culture on adherent IgG or culture with i.v.Ig preparations. Our initial studies failed to show increased IL-1ra levels in the peripheral circulation of patients with Kawasaki's Disease after i.v.Ig administration. However, our preliminary approaches may not have been sufficiently complete and a more extensive examination of the effects of i.v.Ig on IL-1ra production in vivo is warranted.
总之，白细胞介素-1受体拮抗剂（IL-1ra）是一种独特的细胞因子，它能与白细胞介素-1（IL-1）的细胞表面受体紧密结合，却不诱导任何可检测到的细胞内反应。黏附的免疫球蛋白G（IgG）和脂多糖（LPS）通过不同机制诱导人单核细胞产生IL-1ra。在体外和体内，IL-1ra均已被证明是IL-1的有效竞争性抑制剂（阿伦德，1993年）。在内源性IL-1可能在病理生理学中起重要作用的人类疾病中，刺激或增强内源性IL-1ra的产生可能是一种有效的治疗方法。我们的研究表明，在体外，通过在黏附的IgG上培养或与静脉注射免疫球蛋白（i.v.Ig）制剂培养，可诱导人单核细胞产生IL-1ra。我们最初的研究未能显示静脉注射免疫球蛋白后川崎病患者外周循环中IL-1ra水平升高。然而，我们初步的方法可能不够完善，因此有必要更广泛地研究静脉注射免疫球蛋白对体内IL-1ra产生的影响。
